Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Sequence to Structure Approach of Estrogen Receptor Alpha and Ligand Interactions

  • Chamkasem, Aekkapot (Faculty of Veterinary Science, Mahidol University) ;
  • Toniti, Waraphan (Department of Pre-clinic and Applied Animal Sciences, Faculty of Veterinary Science, Mahidol University)
  • Published : 2015.04.03
Download PDF
⟨ Previous Next ⟩

Abstract

Estrogen receptors (ERs) are steroid receptors located in the cytoplasm and on the nuclear membrane. The sequence similarities of human $ER{\alpha}$, mouse $ER{\alpha}$, rat $ER{\alpha}$, dog $ER{\alpha}$, and cat $ER{\alpha}$ are above 90%, but structures of $ER{\alpha}$ may different among species. Estrogen can be agonist and antagonist depending on its target organs. This hormone play roles in several diseases including breast cancer. There are variety of the relative binding affinity (RBA) of ER and estrogen species in comparison to $17{\beta}-estradiol$ (E2), which is a natural ligand of both $ER{\alpha}$ and $ER{\beta}$. The RBA of the estrogen species are as following: diethyl stilbestrol (DES) > hexestrol > dienestrol > $17{\beta}-estradiol$ (E2) > 17- estradiol > moxestrol > estriol (E3) >4-OH estradiol > estrone-3-sulfate. Estrogen mimetic drugs, selective estrogen receptor modulators (SERMs), have been used as hormonal therapy for ER positive breast cancer and postmenopausal osteoporosis. In the postgenomic era, in silico models have become effective tools for modern drug discovery. These provide three dimensional structures of many transmembrane receptors and enzymes, which are important targets of de novo drug development. The estimated inhibition constants (Ki) from computational model have been used as a screening procedure before in vitro and in vivo studies.

Keywords

References

  1. Anstead GM, Carlson KE, Katzenellenbogen JA (1997). The estradiol pharmacophore: ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site. Steroids, 62, 268-303. https://doi.org/10.1016/S0039-128X(96)00242-5
  2. Arnal JF, Valera MC, Payrastre B, et al (2012). Structure-function relationship of estrogen receptors in cardiovascular pathophysiological models. Thromb Res, 130, 7-11. https://doi.org/10.1016/j.thromres.2011.09.022
  3. Ascenzi P, Bocedi A, Marino M (2006). Structure-function relationship of estrogen receptor alpha and beta: impact on human health. Mol Aspects Med, 27, 299-402. https://doi.org/10.1016/j.mam.2006.07.001
  4. Barkhem T, Carlsson B, Nilsson Y, et al (1998). Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. Mol Pharmacol, 54, 105-12.
  5. Berman HM, Westbrook J, Feng Z, et al (2000). The Protein Data Bank. Nucleic Acids Res, 28, 235-42. https://doi.org/10.1093/nar/28.1.235
  6. Bollig-Fischer A, Thakur A, Sun Y, et al (2012). The Predominant Proteins that React to the MC-20 Estrogen Receptor Alpha Antibody Differ in Molecular Weight between the Mammary Gland and Uterus in the Mouse and Rat. Int J Biomed Sci, 8, 51-63.
  7. Brzozowski AM, Pike AC, Dauter Z, et al (1997). Molecular basis of agonism and antagonism in the oestrogen receptor. Nature, 389, 753-8. https://doi.org/10.1038/39645
  8. Cao X, Jiang J, Zhang S, et al (2013). Discovery of natural estrogen receptor modulators with structure-based virtual screening. Bioorg Med Chem Lett, 23, 3329-33. https://doi.org/10.1016/j.bmcl.2013.03.105
  9. Chakraborty S, Cole S, Rader N, et al (2012). In silico design of peptidic inhibitors targeting estrogen receptor alpha dimer interface. Mol Divers, 16, 441-51. https://doi.org/10.1007/s11030-012-9378-x
  10. Chitrala KN, Yeguvapalli S (2013). Prediction and analysis of ligands against estrogen related receptor alpha. Asian Pac J Cancer Prev, 14, 2371-5. https://doi.org/10.7314/APJCP.2013.14.4.2371
  11. Czeczuga-Semeniuk E, Jarzabek K, Lemancewicz D, et al (2009). The vitamin A family can significantly decrease the expression of ERbeta of ERs positive breast cancer cells in the presence or absence of ER ligands and paclitaxel. Gynecol Endocrinol, 25, 287-93. https://doi.org/10.1080/09513590802530924
  12. D'Amelio P, Isaia GC (2013). The use of raloxifene in osteoporosis treatment. Expert Opin Pharmacother, 14, 949-56. https://doi.org/10.1517/14656566.2013.782002
  13. de Villiers TJ, Gass ML, Haines CJ, et al (2013). Global Consensus Statement on menopausal hormone therapy. Maturitas, 74, 391-2. https://doi.org/10.1016/j.maturitas.2013.02.001
  14. Eliassen AH, Hendrickson SJ, Brinton LA, et al (2012). Circulating carotenoids and risk of breast cancer: pooled analysis of eight prospective studies. J Natl Cancer Inst, 104, 1905-16. https://doi.org/10.1093/jnci/djs461
  15. Frasor J, Barnett DH, Danes JM, et al (2003). Response-specific and ligand dose-dependent modulation of estrogen receptor (ER) alpha activity by ERbeta in the uterus. Endocrinol, 144, 3159-66. https://doi.org/10.1210/en.2002-0143
  16. Gangloff M, Ruff M, Eiler S, et al (2001). Crystal structure of a mutant hERalpha ligand-binding domain reveals key structural features for the mechanism of partial agonism. J Biol Chem, 276, 15059-65. https://doi.org/10.1074/jbc.M009870200
  17. Gaudet P, Lane L, Fey P, et al (2009). Collaborative annotation of genes and proteins between UniProtKB/Swiss-Prot and dictyBase. Database (Oxford), 2009, 16.
  18. Hendrickson SJ, Hazra A, Chen C, et al (2012). beta-Carotene 15,15'-monooxygenase 1 single nucleotide polymorphisms in relation to plasma carotenoid and retinol concentrations in women of European descent. Am J Clin Nutr, 96, 1379-89. https://doi.org/10.3945/ajcn.112.034934
  19. Illera JC, Perez-Alenza MD, Nieto A, et al (2006). Steroids and receptors in canine mammary cancer. Steroids, 71, 541-8. https://doi.org/10.1016/j.steroids.2005.11.007
  20. Kuiper G, Carlsson B, Grandien K, et al (1997). Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinol, 138, 863-70.
  21. Kumar R, Thompson EB (1999). The structure of the nuclear hormone receptors. Steroids, 64, 310-9. https://doi.org/10.1016/S0039-128X(99)00014-8
  22. Kumar R, Zakharov MN, Khan SH, et al (2011). The dynamic structure of the estrogen receptor. J Amino Acids, 2011, 812540.
  23. LaFrate AL, Carlson KE, Katzenellenbogen JA (2009). Steroidal bivalent ligands for the estrogen receptor: design, synthesis, characterization and binding affinities. Bioorg Med Chem, 17, 3528-35. https://doi.org/10.1016/j.bmc.2009.04.016
  24. Leinonen R, Nardone F, Zhu W, et al (2006). UniSave: the UniProtKB sequence/annotation version database. Bioinformatics, 22, 1284-5. https://doi.org/10.1093/bioinformatics/btl105
  25. Lewis DF, Ogg MS, Goldfarb PS, et al (2002). Molecular modelling of the human glucocorticoid receptor (hGR) ligand-binding domain (LBD) by homology with the human estrogen receptor alpha (hERalpha) LBD: quantitative structure-activity relationships within a series of CYP3A4 inducers where induction is mediated via hGR involvement. J Steroid Biochem Mol Biol, 82, 195-9. https://doi.org/10.1016/S0960-0760(02)00158-9
  26. Li X, Huang J, Yi P, et al (2004). Single-chain estrogen receptors (ERs) reveal that the ERalpha/beta heterodimer emulates functions of the ERalpha dimer in genomic estrogen signaling pathways. Mol Cell Biol, 24, 7681-94. https://doi.org/10.1128/MCB.24.17.7681-7694.2004
  27. Madeira KP, Daltoe RD, Sirtoli GM, et al (2012). Comparison of immunohistochemical analysis with estrogen receptor SP1 and 1D5 monoclonal antibodies in breast cancer. Pathol Res Pract, 208, 657-61. https://doi.org/10.1016/j.prp.2012.07.010
  28. Maggiolini M, Bonofiglio D, Marsico S, et al (2001). Estrogen receptor alpha mediates the proliferative but not the cytotoxic dose-dependent effects of two major phytoestrogens on human breast cancer cells. Mol Pharmacol, 60, 595-602.
  29. Meshram RJ, Bhiogade NH, Gacche RN, et al (2012). Virtual screening and docking exploration on estrogen receptor: An in silico approach to decipher novel anticancer agents. Indian J Biotechnol, 11, 389-95.
  30. Millanta F, Calandrella M, Bari G, et al (2005). Comparison of steroid receptor expression in normal, dysplastic, and neoplastic canine and feline mammary tissues. Res Vet Sci, 79, 225-32. https://doi.org/10.1016/j.rvsc.2005.02.002
  31. Nam K, Marshall P, Wolf RM, et al (2003). Simulation of the different biological activities of diethylstilbestrol (DES) on estrogen receptor alpha and estrogen-related receptor gamma. Biopolymers, 68, 130-8. https://doi.org/10.1002/bip.10307
  32. Nam KH, Huang Q, Ke A (2012). Nucleic acid binding surface and dimer interface revealed by CRISPR-associated CasB protein structures. FEBS Lett, 586, 3956-61. https://doi.org/10.1016/j.febslet.2012.09.041
  33. Nose T, Tokunaga T, Shimohigashi Y (2009). Exploration of endocrine-disrupting chemicals on estrogen receptor alpha by the agonist/antagonist differential-docking screening (AADS) method: 4-(1-adamantyl)phenol as a potent endocrine disruptor candidate. Toxicol Lett, 191, 33-9. https://doi.org/10.1016/j.toxlet.2009.08.001
  34. Osborne CK, Zhao H, Fuqua SA (2000). Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol, 18, 3172-86.
  35. Pieper U, Eswar N, Braberg H, et al (2004). MODBASE, a database of annotated comparative protein structure models, and associated resources. Nucleic Acids Res, 32, 217-22.
  36. Pike AC, Brzozowski AM, Hubbard RE, et al (1999). Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J, 18, 4608-18. https://doi.org/10.1093/emboj/18.17.4608
  37. Rehm S, Solleveld HA, Portelli ST, et al (2007). Histologic changes in ovary, uterus, vagina, and mammary gland of mature beagle dogs treated with the SERM idoxifene. Birth Defects Res B Dev Reprod Toxicol, 80, 225-32. https://doi.org/10.1002/bdrb.20119
  38. Rustici G, Kolesnikov N, Brandizi M, et al (2013). ArrayExpress update--trends in database growth and links to data analysis tools. Nucleic Acids Res, 41, 987-90. https://doi.org/10.1093/nar/gks1174
  39. Rybalchenko V, Grillo MA, Gastinger MJ, et al (2009). The unliganded long isoform of estrogen receptor beta stimulates brain ryanodine receptor single channel activity alongside with cytosolic Ca2+. J Recept Signal Transduct Res, 29, 326-41. https://doi.org/10.3109/10799890903295168
  40. Schnell S, Mendoza C (2001). A fast method to estimate kinetic constants for enzyme inhibitors. Acta Biotheor, 49, 109-13. https://doi.org/10.1023/A:1010219527831
  41. Shiau AK, Barstad D, Loria PM, et al (1998). The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell, 95, 927-37. https://doi.org/10.1016/S0092-8674(00)81717-1
  42. Sievers F, Wilm A, Dineen D, et al (2011). Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol Syst Biol, 7, 539.
  43. Stump AL, Kelley KW, Wensel TM (2007). Bazedoxifene: a third-generation selective estrogen receptor modulator for treatment of postmenopausal osteoporosis. Ann Pharmacother, 41, 833-9. https://doi.org/10.1345/aph.1H428
  44. Suganya J, Radha M, Naorem DL, et al (2014). In Silico docking studies of selected flavonoids-- natural healing agents against breast cancer. Asian Pac J Cancer Prev, 15, 8155-9. https://doi.org/10.7314/APJCP.2014.15.19.8155
  45. Thompson JD, Higgins DG, Gibson TJ (1994). CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res, 22, 4673-80. https://doi.org/10.1093/nar/22.22.4673
  46. Toniti W, Suthiyotha N, Puchadapirom P, et al (2011). Binding capacity of ER-alpha ligands and SERMs: comparison of the human, dog and cat. Asian Pac J Cancer Prev, 12, 2875-9.
  47. Touraine P (2003). [SERMs and uterus]. Ann Med Interne (Paris), 154, 103-8.
  48. Tremollieres F, Lopes P (2002). [Specific estrogen receptor modulators (SERMs)]. Presse Med, 31, 1323-8.
  49. UniProt C (2014). Activities at the Universal Protein Resource (UniProt). Nucleic Acids Res, 42, 191-8. https://doi.org/10.1093/nar/gkt1140
  50. Xu CY, Jiang ZN, Zhou Y, et al (2013). Estrogen receptor alpha roles in breast cancer chemoresistance. Asian Pac J Cancer Prev, 14, 4049-52. https://doi.org/10.7314/APJCP.2013.14.7.4049
  51. Zhang X, Spiegelman D, Baglietto L, et al (2012). Carotenoid intakes and risk of breast cancer defined by estrogen receptor and progesterone receptor status: a pooled analysis of 18 prospective cohort studies. Am J Clin Nutr, 95, 713-25. https://doi.org/10.3945/ajcn.111.014415

Cited by

  1. A yeast-based screening assay identifies repurposed drugs that suppress mitochondrial fusion and mtDNA maintenance defects vol.12, pp.2, 2019, https://doi.org/10.1242/dmm.036558